Brain expression of the calcineurin inhibitor RCAN1 (Adapt78)

Center for Immunology and Microbial Disease, The Albany Medical College, Albany, NY 12208, USA.
Archives of Biochemistry and Biophysics (Impact Factor: 3.04). 12/2007; 467(2):185-92. DOI: 10.1016/
Source: PubMed

ABSTRACT RCAN1 (Adapt78) is an endogenous inhibitor of calcineurin, an important intracellular phosphatase that mediates many cellular responses to calcium. RCAN1 is expressed in multiple organs, especially heart, skeletal muscle and brain. In brain, it is thought to be important due to its strong expression, developmental regulation, abundance of target protein (calcineurin), and putative links to multiple brain-related disorders. Surprisingly, however, few studies have examined RCAN1 protein expression here. This has led to some confusion in the field over the exact nature and cell-type expression of isoform 4, the more studied of the two major RCAN1 protein isoforms, in brain. Here we characterize RCAN1 brain isoforms in more detail by assessing their size and distribution under conditions of calcium elevation, a hallmark of the isoform 4 response, and using rodent models to allow for more expanded analyses. We find that the 25-29kDa version of this protein, reported in many non-brain studies, is indeed also present in neurons, and most observable after calcium induction. We also observe that expression of isoform 4 is not specific to neurons, as both microglia and astrocyte cells in culture exhibit a strong induction of isoform 4 protein following calcium stress that is not observable in non-stressed tissue sections. Isoform 1 expression is also observable in a primary glial cell-type (rat microglia). Finally, our observations confirm previous reports of low or non-detectable constitutive isoform expression in non-stressed glia, and of a larger sized, RCAN1 antibody-interacting species. These studies extend and complement previous studies on RCAN isoforms toward better understanding the role of RCAN1 in brain function and as a potential new target for treating calcineurin-related brain disorders.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Regulator of calcineurin 1 (RCAN1) has been implicated in pathogenesis of neurodegeneration and various cancers. Recently, we showed that RCAN1 expression was elevated in Down Syndrome and Alzheimer's disease and its overexpression induced neuronal apoptosis. As NF-κB is an important transcription factor involved in cell survival and RCAN1 played vital roles in cell viability, we examined whether NF-κB regulates RCAN1 gene expression. Our results here showed that the RCAN1 isoform 4 gene transcription can be activated by NF-κB signaling. NF-κB activated RCAN1 isoform 4 gene promoter. Luciferase assay, electrophoretic mobility shift assay (EMSA) and chromatin immunoprecipitation identified a NF-κB responsive element in the region of -576-554bp of the RCAN1 isoform 4 promoter. Activation of RCAN1 gene expression by NF-κB is independent from the calcineurin-NFAT signaling since the NF-κB responsive element was distinct from the NFAT binding sites that was previously identified in the region of -350-166bp. Indeed, activation of calcineurin-NFAT signaling decreased NF-κB transcriptional activity, while activation of NF-κB elevated NFAT transcriptional activity. RCAN1 isoform 4 gene transcription was repressed by its own protein expression in a negative feedback loop. Our findings about RCAN1 gene transcription regulated by NF-κB further supported the vital roles of RCAN1 in cellular functions and its involvement in AD pathogenesis.
    Current Alzheimer research 12/2013; 11(2). DOI:10.2174/1567205010666131212114907 · 3.80 Impact Factor
  • Source
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Atherosclerosis, one of the main causes of cardiovascular diseases, is a complex process that involves manifold factors. Besides the vascular lipids accumulation, inflammatory factors could be considered as a proatherogenic factor – RCAN1. RCAN1 is a regulator of calcineurin, both of them being calcium dependent proteins. Recent studies have shown that RCAN1 has an important role in heart valve development. In the same time researchers found that, the atherosclerotic plaques have an up-regulated RCAN1 gene expression. In the near future, it is desirable to elucidate the RCAN1 function and classify it as a possible biochemical marker to diagnose infancy atherosclerosis. Abbreviations: RCAN1 = regulator of calcineurin, LDL = low density lipoproteins, HMG-CoA – 3 = hydroxy-3-methylglutaryl coenzyme A, VSMCs = vascular smooth muscle cells, PDGF = platelet-derived growth factor, FGF = fibroblast growth factor, EGF = epidermal growth factor, IGF = insulin-like growth factor, VEGF = vascular endothelial growth factor, NFAT = nuclear factor of activated T cells, IL-2, IL-6, IL-10, IL-12 = interleukin type 2, 6, 10, 12, AP-1 = activator protein 1, Mef-2 = myocyte enhancer factor-2, GATA-4 = transcription factor, CK1 = casein kinase 1, GSK3 = glycogen synthase kinase 3, DYRK = dual specificity tyrosine phosphorylation regulated kinase, DSCR1 = Down Syndrome Critical Region 1, MCIP1 = myocyte-enriched calcineurin-interacting protein, MLP = muscle lim protein, cAMP = cyclic adenosine monophosphate, PC12 = pheochromocytoma, NMR = nuclear magnetic resonance, SOD = superoxide dismutase, APP = amyloid precursor protein, eNOS = nitric oxide endothelial synthase, Cygb = cytoglobin, HUVEC = human umbilical vein endothelial cells, VDR = vitamin D receptor
    Journal of medicine and life 10/2014; 7(4):481-487.